European regulatory committee recommends the suspension of marketing authorisation for some linear GBCAs

Several years ago the world of contrast- based MRI was concerned by the occurrence of Nephrogenic Systemic Fibrosis (NSF) — a potentially serious

scarring condition in patients with kidney impairment — associated with the administration of Gadolinium Based Contrast Agents (GBCAs) in patients

with impaired renal function. Studies into NSF prompted the categorisation of GBCAs into low-, mid- and high-risk categories depending on the chemical structure

of the molecule used to chelate the gadolinium ion itself

Read More